VitaSpring 10-Q: Going Concern Doubt, $2.25M Working Capital Deficit, and Unremediated Material Weakness
VSBC is trading near its 52-week low of $0.011 (0.0% above the low) on light trading volume (0.3× avg).
Summary
VitaSpring Biomedical's Q2 10-Q reveals a going concern warning, $13,367 in cash, a $2.25 million working capital deficit, and an unremediated material weakness in financial controls.
Key Events · Earnings and Guidance · VSBC
-
Going Concern Doubt
Management concluded substantial doubt exists about the company's ability to continue as a going concern within one year. Cash of $13,367, working capital deficit of $2,251,229, and accumulated deficit of $5,928,532 as of July 31, 2026.
-
Material Weakness Unremediated
Insufficient segregation of duties and lack of U.S. GAAP/SEC reporting expertise remain unremediated as of July 31, 2026, increasing risk of material misstatements.
-
Related-Party Debt Restructured
$2,411,000 owed to a related-party supplier was deferred interest-free for 24 months via a Troubled Debt Restructuring (TDR) dated May 18, 2026, reclassified from current to long-term liability.
-
Rule 15c2-11 Non-Compliance
The company is not compliant with Rule 15c2-11 and intends to engage a market maker to file Form 211 with FINRA in September 2026; until then, broker-dealers may not publish quotations, impairing liquidity and equity raising.
Analysis · VSBC · Industrial Applications And Services
This quarterly report confirms the company is in severe financial distress. Cash of just $13,367 against $2.27 million in current liabilities, a $5.9 million accumulated deficit, and management's own conclusion that substantial doubt exists about its ability to continue as a going concern. The material weakness in internal controls remains unremediated, and the company is not compliant with Rule 15c2-11, which impairs trading liquidity and its ability to raise equity. The $2.4 million related-party payable was restructured as a TDR and deferred to May 2028, but the company still has no committed financing and no revenue. This filing quantifies the survival risk that the prior 8-K only hinted at.
How filings like this one have moved
In the 30 days to Sep 17, 2026, 39.9% of the 373 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.55%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VSBC was trading at $0.01 on OTC in the Industrial Applications And Services sector, with a market capitalization of approximately $2.3M. The 52-week trading range was $0.01 to $19.50. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.